<article xmlns="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle http://dtd.nlm.nih.gov/2.0/xsd/archivearticle.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Mol Biol</journal-id>
      <journal-title-group>
        <journal-title>Journal of Molecular Biology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0022-2836</issn>
      <issn pub-type="epub">1089-8638</issn>
      <publisher>
        <publisher-name>Elsevier</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3145977</article-id>
      <article-id pub-id-type="pmid">21501622</article-id>
      <article-id pub-id-type="publisher-id">YJMBI62971</article-id>
      <article-id pub-id-type="doi">10.1016/j.jmb.2011.03.075</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Thermostabilisation of an Agonist-Bound Conformation of the Human Adenosine A<sub>2A</sub> Receptor</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lebon</surname>
            <given-names>Guillaume</given-names>
          </name>
          <xref rid="af0005" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bennett</surname>
            <given-names>Kirstie</given-names>
          </name>
          <xref rid="af0010" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jazayeri</surname>
            <given-names>Ali</given-names>
          </name>
          <xref rid="af0010" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tate</surname>
            <given-names>Christopher G.</given-names>
          </name>
          <email>cgt@mrc-lmb.cam.ac.uk</email>
          <xref rid="af0005" ref-type="aff">1</xref>
          <xref rid="cr0005" ref-type="corresp">⁎</xref>
        </contrib>
      </contrib-group>
      <aff id="af0005"><label>1</label>MRC Laboratory of Molecular Biology, Hills Road, CB2 0QH Cambridge, UK</aff>
      <aff id="af0010"><label>2</label>Heptares Therapeutics, BioPark, Broadwater Road, Welwyn Garden City AL7 3AX, UK</aff>
      <author-notes>
        <corresp id="cr0005"><label>*</label>Corresponding author. <email>cgt@mrc-lmb.cam.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>10</day>
        <month>6</month>
        <year>2011</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <pub-date pub-type="ppub">
        <day>10</day>
        <month>6</month>
        <year>2011</year>
      </pub-date>
      <volume>409</volume>
      <issue>3</issue>
      <fpage>298</fpage>
      <lpage>310</lpage>
      <history>
        <date date-type="received">
          <day>7</day>
          <month>2</month>
          <year>2011</year>
        </date>
        <date date-type="rev-recd">
          <day>31</day>
          <month>3</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>31</day>
          <month>3</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2011 Elsevier Ltd.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <copyright-holder/>
        <license>
          <license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>The adenosine A<sub>2A</sub> receptor (A<sub>2A</sub>R) is a G-protein-coupled receptor that plays a key role in transmembrane signalling mediated by the agonist adenosine. The structure of A<sub>2A</sub>R was determined recently in an antagonist-bound conformation, which was facilitated by the T4 lysozyme fusion in cytoplasmic loop 3 and the considerable stabilisation conferred on the receptor by the bound inverse agonist ZM241385. Unfortunately, the natural agonist adenosine does not sufficiently stabilise the receptor for the formation of diffraction-quality crystals. As a first step towards determining the structure of A<sub>2A</sub>R bound to an agonist, the receptor was thermostabilised by systematic mutagenesis in the presence of the bound agonist [<sup>3</sup>H]5'-N-ethylcarboxamidoadenosine (NECA). Four thermostabilising mutations were identified that when combined to give mutant A<sub>2A</sub>R-GL26, conferred a greater than 200-fold decrease in its rate of unfolding compared to the wild-type receptor. Pharmacological analysis suggested that A<sub>2A</sub>R-GL26 is stabilised in an agonist-bound conformation because antagonists bind with up to 320-fold decreased affinity. None of the thermostabilising mutations are in the ZM241385 binding pocket, suggesting that the mutations affect ligand binding by altering the conformation of the receptor rather than through direct interactions with ligands. A<sub>2A</sub>R-GL26 shows considerable stability in short-chain detergents, which has allowed its purification and crystallisation.</p>
      </abstract>
      <abstract abstract-type="graphical">
        <fig id="f0035" position="anchor">
          <graphic xlink:href="fx1"/>
        </fig>
      </abstract>
      <kwd-group>
        <title>Abbreviations</title>
        <kwd>GPCR, G-protein-coupled receptor</kwd>
        <kwd>A<sub>2A</sub>R, A<sub>2A</sub> receptor</kwd>
        <kwd>T4L, T4 lysozyme</kwd>
        <kwd>β<sub>1</sub>AR, β<sub>1</sub> adrenoceptor</kwd>
        <kwd>TM, transmembrane region</kwd>
        <kwd>DM, <italic>n</italic>-decyl-β-<sc>d-</sc>maltopyranoside</kwd>
        <kwd>CHO, Chinese hamster ovary</kwd>
        <kwd>NG, nonylglucoside</kwd>
        <kwd>EDTA, ethylenediaminetetraacetic acid</kwd>
        <kwd>FBS, fetal bovine serum</kwd>
        <kwd>WT, wild type</kwd>
        <kwd>DDM, <italic>n</italic>-dodecyl-β-<sc>d</sc>-maltopyranoside</kwd>
        <kwd>NECA, 5'-N-ethylcarboxamidoadenosine</kwd>
      </kwd-group>
      <kwd-group>
        <title>
          <bold>Keywords</bold>
        </title>
        <kwd>conformational thermostabilisation</kwd>
        <kwd>G-protein-coupled receptors</kwd>
        <kwd>membrane protein</kwd>
        <kwd>structure</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="s0005">
      <title>Introduction</title>
      <p>G-protein-coupled receptors (GPCRs) are the largest superfamily of transmembrane receptors with more than 800 members found in humans.<xref rid="bb0005" ref-type="bibr"><sup>1</sup></xref> They are key proteins in human physiology because they are the receptors for a wide variety of signalling molecules (agonists) such as hormones, neurotransmitters, lipids and nucleotides. Agonist binding to GPCRs causes a conformational change that allows coupling of either G proteins or β-arrestin and their subsequent activation,<xref rid="bb0010 bb0015" ref-type="bibr"><sup>2,3</sup></xref> resulting in increased concentrations of intracellular second messengers such as cAMP and Ca<sup>2+</sup>. The pivotal role of GPCRs in intercellular communication makes them important targets for the development of drugs.<xref rid="bb0020 bb0025" ref-type="bibr"><sup>4,5</sup></xref> Understanding how different classes of ligands (e.g., agonist, partial agonist, or inverse agonist) bind to receptors and how they affect the conformation of the receptor has been the goal of research for many decades. Recent successes in the structure determination of hormone-binding GPCRs have identified how antagonists are recognised by the receptors.<xref rid="bb0030 bb0035 bb0040 bb0045 bb0050 bb0055" ref-type="bibr"><sup>6–11</sup></xref> In addition, recent structures of the β<sub>1</sub> adrenoceptor (β<sub>1</sub>AR) and β<sub>2</sub> adrenoceptor bound to agonists have given us the first insights<xref rid="bb0060 bb0065 bb0070" ref-type="bibr"><sup>12–14</sup></xref> into how agonists increase the probability of a receptor being in the R⁎ state (G-protein-coupling conformation) as opposed to the inverse agonist state R (G proteins unable to be activated).</p>
      <p>Extracellular adenosine influences cellular function throughout the body, particular during cellular stresses such as anoxia, but in the central nervous system, it functions as a ubiquitous neuromodulator.<xref rid="bb0075" ref-type="bibr"><sup>15</sup></xref> There are four adenosine receptors found in humans, A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub> and A<sub>3</sub>, which belong to the GPCR family A. The A<sub>1</sub>, A<sub>2A</sub> and A<sub>2B</sub> receptors are well known for being inhibited by the antagonist caffeine.<xref rid="bb0080" ref-type="bibr"><sup>16</sup></xref> Adenosine receptors are implicated in the pathophysiology of many neurological disorders such as Parkinson's disease, Huntington's disease as well as ischemia (cerebral and cardiac) and inflammatory and immune diseases.<xref rid="bb0085 bb0090" ref-type="bibr"><sup>17,18</sup></xref> The adenosine A<sub>2A</sub> receptor (A<sub>2A</sub>R) is therefore a potential target for treating many diseases, with the most advanced drug, preladenant, currently in phase III clinical trials for the treatment of Parkinson's disease.<xref rid="bb0095" ref-type="bibr"><sup>19</sup></xref></p>
      <p>A structure of A<sub>2A</sub>R has been determined with the inverse agonist ZM241385 bound.<xref rid="bb0040" ref-type="bibr"><sup>8</sup></xref> The structure consisted of a receptor T4 lysozyme (T4L) fusion protein crystallised in lipidic cubic phase. Intracellular loop 3 in GPCRs has variable length and may be flexible before coupling to the G protein. Engineering of T4L into this loop produced a chimaeric receptor, A<sub>2A</sub>-T4L, which retains its ability to bind both agonists and antagonists, although this modified receptor binds agonists with higher affinity compared to wild-type (WT) A<sub>2A</sub>R;<xref rid="bb0040" ref-type="bibr"><sup>8</sup></xref> thus, its conformation may be slightly biased towards the agonist-bound state. A<sub>2A</sub>-T4L was crystallised in the presence of the high-affinity inverse agonist ZM241385 to help stabilise the detergent-solubilised A<sub>2A</sub>R. With its pharmacology favouring agonist binding in comparison to the WT receptor yet being crystallised with a tightly bound inverse agonist, the exact state of the crystallised complex is therefore open to debate. Another problem is that when low-affinity agonists bind to GPCRs, the agonist–receptor complex is often less stable than the antagonist–receptor complex,<xref rid="bb0100" ref-type="bibr"><sup>20</sup></xref> making it more difficult to crystallise and produce well-diffracting crystals. Therefore, to obtain the structure of A<sub>2A</sub>R with an agonist bound, we have extensively stabilised A<sub>2A</sub>R in a specific agonist-binding conformation.</p>
      <p>Conformational thermostabilisation is a strategy used to engineer a membrane protein so that it is sufficiently stable in short-chain detergent for crystallisation and structure determination. The strategy has been applied to the thermostabilisation of the β<sub>1</sub>AR,<xref rid="bb0105 bb0110" ref-type="bibr"><sup>21,22</sup></xref> the neurotensin receptor (NTS1)<xref rid="bb0115" ref-type="bibr"><sup>23</sup></xref> and A<sub>2A</sub>R.<xref rid="bb0120 bb0125" ref-type="bibr"><sup>24,25</sup></xref> In each instance, it was observed that, if the selection for thermostabilising mutations was performed with an antagonist, then the thermostabilised mutant was preferentially in an antagonist-binding conformation; similarly, selection with an agonist resulted in a receptor in the agonist-binding conformation. Since there are distinctive structural differences between the agonist- and the antagonist-binding conformations, it is of little surprise that different mutations are required to stabilise the two different states.<xref rid="bb0120" ref-type="bibr"><sup>24</sup></xref> Stabilisation of β<sub>1</sub>AR and A<sub>2A</sub>R in the antagonist-bound conformation allowed the crystallisation and structure determination of both receptors<xref rid="bb0045" ref-type="bibr"><sup>9</sup></xref> (Dore <italic>et al</italic>., unpublished data). In contrast, thermostabilisation with agonists has proved to be more difficult. In the case of NTS1, the receptor was clearly thermostabilised, but on purification, the receptor tended to aggregate.<xref rid="bb0115" ref-type="bibr"><sup>23</sup></xref> This was ascribed to the stabilisation of the receptor simultaneously in both a ligand-free conformation and an agonist-bound conformation, thus resulting in a mutant that can undergo changes in structure upon ligand binding rather than being locked in a single conformation. Here, we describe a modified strategy for the stabilisation of A<sub>2A</sub>R in an agonist-bound conformation. The stabilised receptor A<sub>2A</sub>R-GL26 is now extremely stable in short-chain detergents when the agonist 5'-N-ethylcarboxamidoadenosine (NECA) is bound, and this has allowed its purification in a monodisperse state and its subsequent crystallisation.</p>
    </sec>
    <sec id="s0010">
      <title>Results</title>
      <sec id="s0015">
        <title>Identification of thermostabilising point mutations in agonist-bound A<sub>2A</sub>R</title>
        <p>The strategy used to identify thermostabilising mutations involves creating a library of mutants throughout the receptor where every amino acid residue is changed to alanine or, if the residue is already alanine, to leucine. Each mutant receptor is then expressed and solubilised in detergent and has its thermostability determined by measuring the amount of receptor remaining after heating the sample for 30 min at a given temperature. A “thermostable” mutant in this context is therefore used to describe a mutated receptor with a decreased rate of unfolding, and the term thermostable is not meant to imply anything with respect to the thermodynamic properties of the receptor. In the previously published method<xref rid="bb0120" ref-type="bibr"><sup>24</sup></xref> to select mutations to produce a thermostable agonist-bound conformation of A<sub>2A</sub>R, the thermostability was determined by heating the detergent-solubilised receptor in the absence of ligand, quenching on ice and then performing a ligand binding assay using the agonist [<sup>3</sup>H]NECA. Thermostabilising mutations were identified (<xref rid="f0005" ref-type="fig">Fig. 1</xref>) and combined to construct the mutant A<sub>2A</sub>R-Rag23, which was 9 °C more thermostable than the WT receptor. Although significant, this small increase in stability was considered insufficient to guarantee success in structure determination. In the interim, it was found that heating the receptor in the thermostability assay in the presence of <sup>3</sup>H-labeled agonist produced mutants with a greater increase in stability.<xref rid="bb0115" ref-type="bibr"><sup>23</sup></xref> Therefore, we rescreened all 315 point mutations made previously<xref rid="bb0120" ref-type="bibr"><sup>24</sup></xref> by heating the detergent-solubilised mutants in the presence of [<sup>3</sup>H]NECA (see <xref rid="s0040" ref-type="sec">Methods</xref>).</p>
        <p>A necessary prerequisite to screen for [<sup>3</sup>H]NECA-bound themostabilising mutants was to define an optimum buffer to favour the formation of the receptor–agonist complex. The <italic>K</italic><sub>d</sub> for NECA binding to A<sub>2A</sub>R is reduced by high concentrations of detergent or NaCl, and the thermostability of [<sup>3</sup>H]NECA-bound A<sub>2A</sub>R is similarly reduced under these conditions.<xref rid="bb0120" ref-type="bibr"><sup>24</sup></xref> Therefore, the thermostability assay developed contained low concentrations of <italic>n</italic>-dodecyl-β-<sc>d</sc>-maltopyranoside (DDM) and no NaCl. After solubilisation in DDM, A<sub>2A</sub>R was bound to Ni<sup>2+</sup>-NTA resin, washed to reduce the DDM concentration and then eluted (see <xref rid="s0040" ref-type="sec">Methods</xref>). [<sup>3</sup>H]NECA was then added to this partially purified sample, which was then heated at various temperatures for 30 min and quenched on ice, and the receptor-bound ligand was separated from free ligand on a mini gel-filtration column.<xref rid="bb0130" ref-type="bibr"><sup>26</sup></xref> This assay was used to define the stability of the WT receptor (apparent <italic>T</italic><sub>m</sub>) and for the initial screen of all the Ala/Leu scan mutants. We refer to this as the ligand plus format.<xref rid="bb0115" ref-type="bibr"><sup>23</sup></xref> The apparent <italic>T</italic><sub>m</sub> is defined as the temperature at which 50% of the solubilised receptor can still bind radioligand after a 30-min incubation.<xref rid="bb0105 bb0115 bb0120" ref-type="bibr"><sup>21,23,24</sup></xref> The apparent <italic>T</italic><sub>m</sub> for WT A<sub>2A</sub>R using the [<sup>3</sup>H]NECA thermostability assay (see <xref rid="s0040" ref-type="sec">Methods</xref>) is 28.6 ± 0.2 °C (<italic>n</italic> = 8).</p>
        <p>The library of Ala/Leu mutants made throughout A<sub>2A</sub>R<xref rid="bb0120" ref-type="bibr"><sup>24</sup></xref> was then expressed and solubilised in DDM, and a single-point thermostability assay was performed on each mutant by heating the [<sup>3</sup>H]NECA-bound receptor at 28 °C for 30 min; the results of these assays were compared to the thermostability of the WT receptor. Out of the 315 mutants screened, 38 were found to increase the thermostability of [<sup>3</sup>H]NECA-bound A<sub>2A</sub>R by a minimum of 40% and, in addition, maintained a minimum expression level of 30%, both values compared to WT A<sub>2A</sub>R (<xref rid="f0005" ref-type="fig">Fig. 1</xref>). The mutations thermostabilising [<sup>3</sup>H]NECA-bound A<sub>2A</sub>R are, in general, different from the mutants described previously that stabilise the ligand-free A<sub>2A</sub>R selected with [<sup>3</sup>H]NECA, although nine mutations are common to both experiments (<xref rid="f0005" ref-type="fig">Fig. 1</xref>). The apparent <italic>T</italic><sub>m</sub> was then determined for each of the 38 mutants, and the 16 most thermostabilising mutations (<xref rid="t0005" ref-type="table">Table 1</xref>) were selected for further study. The L48A mutant provided the greatest thermostabilisation of the [<sup>3</sup>H]NECA-bound A<sub>2A</sub>R, conferring a 13.6 °C improvement in stability (apparent <italic>T</italic><sub>m</sub> of 42.2 ± 0.75 °C; <xref rid="f0010" ref-type="fig">Fig. 2</xref>); the Ballesteros–Weinstein numbers for all the amino acid residues discussed are presented in <xref rid="t0005" ref-type="table">Table 1</xref>. The remaining 15 mutants improved the thermostability of [<sup>3</sup>H]NECA-bound A<sub>2A</sub>R by 2–6 °C (<xref rid="t0005" ref-type="table">Table 1</xref>). The 16 selected mutations are highly clustered in the primary amino sequence of A<sub>2A</sub>R, with 7 mutations in transmembrane region (TM) 2, 4 in TM3 and 3 in TM6, with only 1 mutation in TM1 and TM7 (<xref rid="f0005" ref-type="fig">Fig. 1</xref>).</p>
        <p>The thermostabilising mutants were then tested for their ability to thermostabilise A<sub>2A</sub>R when the inverse agonist ZM241385 was bound. In theory, if a mutation alters the equilibrium between R and R⁎ so that the agonist-binding conformation R⁎ is preferentially populated, then both the affinity for an inverse agonist and the thermostability of the receptor–inverse agonist complex could potentially be compromised. The apparent <italic>T</italic><sub>m</sub> of [<sup>3</sup>H]ZM241385-bound A<sub>2A</sub>R was 32.0 ± 0.1 °C (<xref rid="t0005" ref-type="table">Table 1</xref>), which is 3.5 °C more stable than that of [<sup>3</sup>H]NECA-bound A<sub>2A</sub>R measured under identical conditions. The 15 mutants that showed the highest thermostabilities in the NECA-bound conformation were tested for thermostability when ZM241385 was bound. The results show that these 15 mutants can be categorised into three classes (<xref rid="t0005" ref-type="table">Table 1</xref>). The first category contained mutants L48A, F62A, F79A and F242A, which did not bind [<sup>3</sup>H]ZM241385 at 4 °C in this experiment, suggesting a dramatic loss of affinity (see below for ligand binding experiments), and their thermostability with [<sup>3</sup>H]ZM241385 bound was not determined. The second category contained mutants S47A, F83A and Q89A, which stabilised the NECA-bound conformation and destabilised the ZM241385-bound conformation. The third group is composed of the remaining mutations that stabilised both agonist- and inverse-agonist-bound conformations (A50L, A54L, V57A, T65A, S90A, A236L, I238A and V282A).</p>
      </sec>
      <sec id="s0020">
        <title>Combining mutants to make the optimally thermostable agonist-bound receptor A<sub>2A</sub>R-GL26</title>
        <p>Given the unusually large increase in thermostability observed for A<sub>2A</sub>R-L48A, it was used as the starting point for the construction of an optimally stable agonist-binding receptor for structural studies, and it was renamed GL0. It has not usually proved possible to predict whether the combination of two thermostabilising point mutations will result in an additive effect on the thermostability or whether they will combine to destabilise the receptor. Therefore, 13 of the remaining thermostabilising point mutations were individually combined with the L48A mutation (<xref rid="t0010" ref-type="table">Table 2</xref>). Previous experience of combining thermostabilising mutations has shown that mutants close to each other in the primary amino acid sequence were often not additive;<xref rid="bb0105 bb0115 bb0120" ref-type="bibr"><sup>21,23,24</sup></xref> thus, the double mutants of L48A with either S47A or A50L were not made. Each of the double mutants was expressed, and its thermostability was measured and compared to the predicted <italic>T</italic><sub>m</sub> [Δ<italic>T</italic><sub>m</sub> for each single mutant (<xref rid="t0010" ref-type="table">Table 2</xref>) summed with the apparent <italic>T</italic><sub>m</sub> for WT A<sub>2A</sub>R]. Five of the double mutants did not increase thermostability compared to the L48A single mutant (<xref rid="f0010" ref-type="fig">Fig. 2</xref>). All of the remaining double mutants showed higher thermostabilities compared to GL0, with the best combination being L48A-Q89A (A<sub>2A</sub>R-GL10) with an apparent <italic>T</italic><sub>m</sub> of 46.7 ± 0.4 °C (<xref rid="f0010" ref-type="fig">Fig. 2</xref>). This strategy was repeated using the double mutant GL10 as the starting point and adding the five mutations found to be additive in the previous round. As previously mentioned, mutating residues close to each other often does not have an additive effect; thus, the S90A mutation was not tested, and in addition, GL10 containing the mutation F83A could not be made. One mutant showed an additive effect for the third mutation, L48A-Q89A-T65A (A<sub>2A</sub>R-GL23), which had an apparent <italic>T</italic><sub>m</sub> of 49.9 ± 0.1 °C (<xref rid="f0010" ref-type="fig">Fig. 2</xref>). It is interesting to note that all the mutations used to construct GL23 are in TM2 and TM3 and that none of the mutations in TM6 were additive with L48A (<xref rid="f0005" ref-type="fig">Fig. 1</xref> and <xref rid="t0010" ref-type="table">Table 2</xref>).</p>
        <p>To improve the thermostability of GL23 further, we changed the detergent used in the thermostability assay to a shorter-chain detergent, <italic>n</italic>-decyl-β-<sc>d-</sc>maltopyranoside (DM). As expected, reducing the size of the detergent decreased the stability of the receptor, with A<sub>2A</sub>R-GL23 being 7.7 °C less stable in DM than in DDM (<xref rid="t0010" ref-type="table">Table 2</xref>). After a last round of mutagenesis combining the additive mutants to GL23, it was found that the addition of A54L to make mutant GL26 yield the highest thermostability. A<sub>2A</sub>R-GL26 displayed very good thermostability in DM (apparent <italic>T</italic><sub>m</sub> of 44.5 ± 0.8 °C) and also excellent stability in a variety of other short-chain detergents ideal for crystallography (<xref rid="f0015" ref-type="fig">Fig. 3</xref>). A<sub>2A</sub>R-GL26 is 21.5 °C more stable than the WT receptor in DM, which has an apparent <italic>T</italic><sub>m</sub> of 23 °C when solubilised in this detergent.<xref rid="bb0120" ref-type="bibr"><sup>24</sup></xref></p>
        <p>An alternative method for displaying the thermostability of the various mutants is shown in <xref rid="f0010" ref-type="fig">Fig. 2</xref>c, which relates the logarithm of the rate of inactivation of the receptor to the temperature (see <xref rid="s0040" ref-type="sec">Methods</xref>). Provided that all the assays are performed under identical conditions, this can be used to estimate the factor by which a receptor is stabilised compared to the WT receptor. Data extracted from <xref rid="f0010" ref-type="fig">Fig. 2</xref>b were therefore replotted in <xref rid="f0010" ref-type="fig">Fig. 2</xref>c and used to estimate that the rate of unfolding of NECA-bound A<sub>2A</sub>R-GL23 was about 230 times slower than that of the NECA-bound WT A<sub>2A</sub>R, implying a 230-fold improvement in the thermostability of A<sub>2A</sub>R-GL23.</p>
      </sec>
      <sec id="s0025">
        <title>Pharmacological characterisation of thermostabilised mutants</title>
        <p>Three of the mutants (GL0, GL23 and GL26) were transiently expressed in Chinese hamster ovary (CHO) cells; the membranes were purified; and competition binding analyses were performed using agonists, an inverse agonist and antagonists, in addition to saturation binding experiments performed with [<sup>3</sup>H]NECA, to characterise how the thermostabilising mutations have affected the conformation of A<sub>2A</sub>R (<xref rid="t0015" ref-type="table">Table 3</xref>). The changes in p<italic>K</italic><sub><italic>i</italic></sub> for each mutant and all ligands tested are summarised in <xref rid="f0020" ref-type="fig">Fig. 4</xref>. All the mutants bound the antagonists CGS15943 and SCH58621, as well as the inverse agonist ZM241385, more weakly (<xref rid="f0020" ref-type="fig">Fig. 4</xref>). In contrast, there was no significant change in affinity for the binding of all the agonists tested (NECA, ATL146e and CGS21680) (<xref rid="f0020" ref-type="fig">Fig. 4</xref>) except that NECA bound three times more tightly to GL23 than to WT A<sub>2A</sub>R (<xref rid="t0015" ref-type="table">Table 3</xref>). The data show that the major influence on the conformation of the ultimate mutant A<sub>2A</sub>R-GL26 is from the L48A mutation in GL0. This single point mutation accounted for 60–88% of the reduction in antagonist affinity observed in GL26.</p>
      </sec>
      <sec id="s0030">
        <title>Purification of the thermostable mutant A<sub>2A</sub>R-GL31</title>
        <p>A<sub>2A</sub>R-GL26 was expressed using the baculovirus expression system in insect cells to give about 2–3 mg/L of cell culture and then purified using a two-step process, a Ni<sup>2+</sup>-NTA column followed by size exclusion chromatography. However, purified GL26 consisted of two species differing in molecular mass by about 3 kDa, which is consistent with only a proportion of the receptor being N-glycosylated (data not shown). Therefore, the predicted N-glycosylation site Asn154 was mutated to Ala to make A<sub>2A</sub>R-GL31 (L48A-Q89A-T65A-A54L-N154A). A<sub>2A</sub>R-GL31 was expressed in insect cells and purified on a Ni<sup>2+</sup>-NTA column, followed by size-exclusion chromatography (<xref rid="f0025" ref-type="fig">Fig. 5</xref>). Even if the size-exclusion column was run using the detergent nonylglucoside (NG), purified A<sub>2A</sub>R-GL31 exhibited a symmetrical peak, which is indicative of a highly purified, monodisperse sample (<xref rid="f0025" ref-type="fig">Fig. 5</xref>). After concentration, one preparation yielded 1 mg of purified receptor from a 2-L culture, and the receptor could be concentrated up to 20 mg/mL without significant aggregation. A<sub>2A</sub>R-GL31 bound to NECA produced good-quality crystals that diffracted isotropically to 2.6 Å resolution (Lebon <italic>et al.</italic>, unpublished data).</p>
      </sec>
    </sec>
    <sec id="s0035">
      <title>Discussion</title>
      <p>Conformational thermostabilisation of GPCRs has proven to be a successful strategy for their structure determination when the receptor is stabilised in the antagonist state, with structures of both a β<sub>1</sub>AR<xref rid="bb0045" ref-type="bibr"><sup>9</sup></xref> and an A<sub>2A</sub>R (Doré <italic>et al</italic>. unpublished data) with antagonists bound having been determined. The real value of the approach was recently highlighted by the structures of β<sub>1</sub>AR bound to low-affinity agonists.<xref rid="bb0070" ref-type="bibr"><sup>14</sup></xref> The other approaches that have also given GPCR structures<xref rid="bb0135" ref-type="bibr"><sup>27</sup></xref> rely on increasing the hydrophilic area of the receptor by binding an antibody fragment and/or with a T4L fusion and on the thermostabilisation of the receptor by formation of a complex with a high-affinity ligand with a slow off-rate.<xref rid="bb0040 bb0140" ref-type="bibr"><sup>8,28</sup></xref> In the case of A<sub>2A</sub>R, we would like to determine its structure bound to its natural agonist, adenosine; thus, thermostabilisation seemed to be the logical approach to take. Two different thermostabilisation procedures have been developed previously for stabilising a GPCR in an agonist-bound conformation, and these gave rise to thermostable mutants A<sub>2A</sub>R-Rag23<xref rid="bb0120" ref-type="bibr"><sup>24</sup></xref> and NTS1-7m,<xref rid="bb0115" ref-type="bibr"><sup>23</sup></xref> but in both cases, the degree of thermostabilisation attained was probably too small to guarantee the formation of well-diffracting crystals. Here, we describe another strategy that produced the mutant A<sub>2A</sub>R-GL26, which is highly thermostable and has already been purified and crystallised. The two significant changes introduced here in relation to previous procedures were, firstly, the use of [<sup>3</sup>H]NECA-bound A<sub>2A</sub>R in the thermostability assay and, secondly, the removal of the requirement for simultaneous stabilisation of the unliganded and NECA-bound conformations. The resulting mutant, A<sub>2A</sub>R-GL26, is similar in stability upon detergent solubilisation to native rhodopsin<xref rid="bb0145" ref-type="bibr"><sup>29</sup></xref> or β<sub>1</sub>AR-m23,<xref rid="bb0105" ref-type="bibr"><sup>21</sup></xref> both of which have been crystallised and their structures determined to high resolution.</p>
      <p>Four mutations were required to thermostabilise A<sub>2a</sub>R in the agonist-bound conformation. The single mutation with the greatest thermostabilising effect was L48A, which increased the stability of NECA-bound A<sub>2A</sub>R by 13.6 °C. The L48A mutant was therefore an obvious candidate to start the thermostabilisation of the A<sub>2A</sub> NECA-bound conformation. The strategy was to make a series of double mutants by adding the best thermostabilising mutants to L48A, testing their thermostability, picking the most thermostable double mutant and then adding the next best single thermostabilising mutation. At each stage, only those single mutations that gave a clear additive increase in thermostability were tested in the next round. Out of 13 double mutants constructed and tested for their thermostability, the L48A-Q89A mutant had the highest thermostability, which was only slightly lower than the <italic>T</italic><sub>m</sub> predicted by adding the Δ<italic>T</italic><sub>m</sub> for Q89A to the <italic>T</italic><sub>m</sub> for L89A. In a similar fashion, T65A was found to further thermostabilise the receptor to make the triple mutant GL23 (L48A-Q89A-T65A) with an apparent <italic>T</italic><sub>m</sub> of 50 °C in DDM. We have sometimes found that the measurement of apparent <italic>T</italic><sub>m</sub> at high temperatures may be less accurate than desired due to nonspecific protein aggregation in the sample; therefore, we decided to carry out one more round of thermostabilisation in DM. As expected, the thermostability of GL23 was lower in DM than in DDM (<xref rid="f0015" ref-type="fig">Fig. 3</xref>). Among the five mutations tested, the best additive effect was observed for the A54L mutant. The final mutant GL26 displays an apparent <italic>T</italic><sub>m</sub> of 44.5 °C in 0.15% DM, which is similar to that observed for the thermostable mutant β<sub>1</sub>AR-m23 (apparent <italic>T</italic><sub>m</sub> of 48 °C).<xref rid="bb0105" ref-type="bibr"><sup>21</sup></xref> A<sub>2A</sub>R-GL26 also displayed considerable stability in relatively harsh detergents such as foscholine-10 (FC10), decanoyl-<italic>N</italic>-hydroxyethylglucamide and <italic>n</italic>-octyl-β-<sc>d</sc>-thioglucopyranoside, which have been used previously to crystallise β<sub>1</sub>AR-m23.<xref rid="bb0150" ref-type="bibr"><sup>30</sup></xref></p>
      <p>In previous thermostabilisation experiments, each receptor was stabilised in a particular conformation depending on whether an agonist or an antagonist was used for the selection of thermostable mutants. The conformation of A<sub>2A</sub>R-GL26 was therefore assessed by performing ligand binding assays using both agonists and antagonists. The binding affinities for the inverse agonist ZM241385 and the antagonist CGS15943 were reduced by 320-fold, whereas the only statistically significant change in agonist binding affinity was observed for NECA (3-fold increase). The affinities for ATL146e and CGS21680 remained similar to those of WT A<sub>2A</sub>R. None of the mutations used to thermostabilise A<sub>2A</sub>R-GL26 are in the ligand binding pocket, which suggests that they acted by affecting the global conformation of the receptor. It is not possible to define exactly which conformational state A<sub>2A</sub>R-GL26 is in, except by determining its structure, but the binding data are consistent with A<sub>2A</sub>R-GL26 being in an agonist-binding conformation. However, it is very unlikely that the conformation is identical with the fully activated state because it would then be expected that agonist affinity would be increased by a factor of 15–40 or more.<xref rid="bb0155 bb0160" ref-type="bibr"><sup>31,32</sup></xref> It is thus anticipated that the receptor will represent a conformation along the activation pathway, between the R state and the R⁎ state.</p>
      <p>Analysis of the ZM241385-bound structure of A<sub>2A</sub>R<xref rid="bb0040" ref-type="bibr"><sup>8</sup></xref> showed that none of the thermostabilising mutants in A<sub>2A</sub>R-GL26 make direct contact to the ligand (Fig. <xref rid="f0030" ref-type="fig">6</xref>). It is therefore likely that the introduction of the four thermostabilising mutations L48A, T65A, Q89A and A54L has induced a conformational change in the receptor, and the binding data support the view that the mutant is in an agonist-binding conformation between R and R⁎. The single biggest effect on ligand binding was seen for the mutation L48A<sup>2.46</sup> (superscript refers to the Ballesteros–Weinstein numbering system<xref rid="bb0165" ref-type="bibr"><sup>33</sup></xref>) with a 2-fold increase in the affinity for the agonist NECA and a 50-fold decrease in affinity for the inverse agonist ZM241385. In the entire GPCR family, Leu<sup>2.46</sup> is one of the most conserved residues in TM2 (approximately L 96%, M 2%, I 1.5% and V/T 0.5%). When mutated to alanine, Leu<sup>2.46</sup> displays constitutive activity in rhodopsin<xref rid="bb0170" ref-type="bibr"><sup>34</sup></xref> and the thyrotropin receptor.<xref rid="bb0175" ref-type="bibr"><sup>35</sup></xref> The side chain of Leu48<sup>2.46</sup> is located near the cytoplasmic end of TM2 and oriented towards the core of the receptor helix bundle close to the NPXXY motif in TM7, which is composed of the highly conserved residues Asn<sup>7.49</sup>, Pro<sup>7.50</sup> and Tyr<sup>7.53</sup>. Leu<sup>2.46</sup> has been described as being involved in a hydrophobic interaction with Asn<sup>7.49</sup>, which may constrain the receptor in an inactive conformation,<xref rid="bb0175" ref-type="bibr"><sup>35</sup></xref> and was suggested to stabilise the ground state of rhodopsin.<xref rid="bb0170" ref-type="bibr"><sup>34</sup></xref> The Q89A mutation was previously reported to increase the affinity of agonists and decrease the affinity for antagonists, perhaps through an indirect effect on the receptor,<xref rid="bb0180" ref-type="bibr"><sup>36</sup></xref> which we also observed here (<xref rid="f0020" ref-type="fig">Fig. 4</xref>). In the crystal structure of A<sub>2A</sub>R bound to ZM241385, both T65A and A54L are located in TM2 facing the lipid bilayer; thus, it is unclear why these mutations are thermostabilising.</p>
      <p>The rationale for thermostabilising membrane proteins is to allow the use of short-chain detergents during both purification and crystallisation, which will improve the probability of success in obtaining well-diffracting crystals that are suitable for structure determination.<xref rid="bb0185" ref-type="bibr"><sup>37</sup></xref> Therefore, the success of any thermostabilisation procedure should be apparent during purification of the mutated receptor because it should not aggregate even if relatively harsh detergents are used. Initial purification of A<sub>2A</sub>R-GL26 showed that the receptor was present as both an unglycosylated and an N-glycosylated product (results not shown); thus, the additional mutation N154A was introduced into A<sub>2A</sub>R-GL26 to make the non-glycosylated mutant A<sub>2A</sub>R-GL31. This was subsequently purified in NG, and the product was monodisperse and pure, showing that the protein was ideal for crystallography. Indeed, crystals were obtained relatively easily and have been improved to diffract to better than 2.6 Å resolution; the structure of A<sub>2A</sub>R-GL31 is currently under refinement. Thus, the simplified thermostabilisation strategy presented here for stabilising the agonist-bound form of GPCRs was successful and should be equally applicable to other GPCRs.</p>
    </sec>
    <sec sec-type="methods" id="s0040">
      <title>Methods</title>
      <sec id="s0045">
        <title>Expression of adenosine A<sub>2A</sub>R point mutants in <italic>Escherichia coli</italic></title>
        <p>The library of Ala/Leu scan mutants in the receptor A<sub>2a</sub>R-(2–316) was expressed from plasmid pRG/III-hs-MBP in <italic>E. coli</italic> strain DH5α as previously described.<xref rid="bb0120" ref-type="bibr"><sup>24</sup></xref> Cells were grown at 37 °C in 2-L flasks containing 500 mL of 2× tryptone–yeast medium supplemented with ampicillin (100 μg/mL) and glucose (0.2% w/v). At an OD<sub>600</sub> of 0.7, IPTG and theophylline were added at final concentrations of 0.5 mM and 100 μM, respectively, and the temperature was reduced to 20 °C. After 22 to 24 h, cells were harvested in aliquots of 14 mL, centrifuged (30 min, 5000<bold><italic>g</italic></bold>) and stored at − 20 °C.</p>
      </sec>
      <sec id="s0050">
        <title>Solubilisation and partial purification of adenosine A<sub>2A</sub>R mutants for thermostability assays</title>
        <p>An aliquot of <italic>E. coli</italic> cells (14 mL) was thawed on ice and resupended in 500 μL of buffer A [50 mM Tris–HCl (pH 7.4), 0.4 M NaCl, 250 μg/mL lysozyme (Sigma) and 1 mg/mL DNase I (Sigma), supplemented with complete ethylenediaminetetraacetic acid (EDTA)-free Protease inhibitor cocktail (Roche)] and incubated for 1 h at 4 °C. Samples were then sonicated for 1 min at 4 °C using a cup-horn sonicator. The receptors were solubilised by adding 1% DDM and incubated for 1 h at 4 °C. Insoluble material was removed by centrifugation (5 min, 13,000<bold><italic>g</italic></bold>, 4 °C). The solubilised receptors were partially purified with Ni-NTA agarose (Qiagen). Agarose beads (300 μL) pre-equilibrated in buffer A were added to 700 μL of solubilised receptor. To reduce the detergent concentration by dilution, we added a solution of 50 mM Tris–HCl, pH 7.4, and 0.4 M NaCl to a final volume of 2 mL. After 2 h of incubation at 4 °C, samples were centrifuged (13,000<bold><italic>g</italic></bold>, 10 s, 4 °C), washed three times in buffer B (25 mM Hepes, pH 7.4, and 0.025% DDM) and then eluted in buffer B supplemented with 50 mM histidine for 30 min at 4 °C. The supernatant was used directly in radioligand binding assay.</p>
      </sec>
      <sec id="s0055">
        <title>Radioligand binding assay and thermostability assay for detergent-solubilised receptors</title>
        <p>Solubilised receptor (108 μL) was mixed with 12 μL of 4 μM [<sup>3</sup>H]NECA (final concentration of 400 nM) or 12 μL of 1 μM [<sup>3</sup>H]ZM241385 (final concentration of 100 nM). Radioligand concentrations used were approximately 10-fold the <italic>K</italic><sub>d</sub> value. The sample was incubated for 45 min at 4 °C, then 30 min at the specified temperature and then 30 min at 4 °C. Receptor-bound and free radioligands were separated as previously described on mini gel-filtration columns.<xref rid="bb0130" ref-type="bibr"><sup>26</sup></xref> Receptor-bound ligands were transferred to a 96-well plate (PerkinElmer) and mixed with 200 μL of Optiphase supermix (PerkinElmer). The bound <sup>3</sup>H-labeled ligand was determined using a 1450 Microbeta Trilux counter (1 min per sample).</p>
      </sec>
      <sec id="s0060">
        <title>Mammalian cell culture and receptor expression</title>
        <p>CHO cells were maintained in culture in Dulbecco's modified Eagle's medium/HAMs F12 media containing 10% fetal bovine serum (FBS). Cells were transfected with either WT adenosine A<sub>2A</sub>R or a stabilised receptor construct using GeneJuice according to the manufacturer's instructions. After 48 h post-transfection, cells were harvested by scraping and centrifuged (200<bold><italic>g</italic></bold>, 5 min, 4 °C). The supernatant was removed, and the pellet was resuspended in 10 mL of 20 mM Hepes buffer + 10 mM EDTA buffer (pH 7.4). The membrane suspension was homogenised (10 s, 20,500 rpm) and centrifuged (200<bold><italic>g</italic></bold>, 15 min, 4 °C). The supernatant was collected, the pellet was resuspended in 10 mL of Hepes/EDTA buffer and the solution was homogenised and centrifuged as described before. The collected supernatant was centrifuged (30 min, 40,000<bold><italic>g</italic></bold>, 4 °C). Pellets were resuspended in 20 mM Hepes, pH 7.4, and 0.1 mM EDTA to a concentration of 1 mg/mL and stored at − 80 °C until further use.</p>
      </sec>
      <sec id="s0065">
        <title>Ligand binding assays, saturation and competition binding experiment</title>
        <p>Membranes from CHO cells transiently expressing receptors (10–15 μg/well) were assessed using competition [<sup>3</sup>H]NECA binding in buffer containing 50 mM Tris–HCl (pH 7.4). Nonspecific binding was defined using 1 μM CGS21680. After 1 h of incubation at 25 °C, assays were terminated by filtration through 96-well GF/B filter plates presoaked with 0.1% polyethyleneimine and washed with 5 × 0.5 mL water. Plates were dried, and bound ligand was measured using a Microbeta counter. Inhibition curves were fitted to a four-parameter logistic equation to determine IC<sub>50</sub> values, which were converted into <italic>K</italic><sub><italic>i</italic></sub> values using <italic>K</italic><sub>d</sub> values determined by saturation binding and the [<sup>3</sup>H]NECA concentration (∼ 10 nM).</p>
      </sec>
      <sec id="s0070">
        <title>Purification of NECA-bound A<sub>2A</sub>R-GL31</title>
        <p>Receptors were expressed with the baculovirus system using cells derived from <italic>Trichoplusia ni</italic> (High 5™) and the vector pBacPAK8 (Invitrogen). Insect cells were grown in suspension in a maximum volume of 500 mL in 2-L roller bottles (Corning) at 27 °C with shaking at 150 rpm. Sf9 cells were grown in TNM-FH medium supplemented with 10% FBS, and Tni cells were grown in EXcell 405 medium supplemented with 5% FBS (heat inactivated); all media were supplemented with 1% lipids (Invitrogen). The GL31 construct was inserted into plasmid pBacPAK8 using the restriction enzyme BamHI/XbaI<italic>.</italic> Sf9 cells were used to generate the first virus passages and to obtain second- and third-passage high-titre virus stocks. Tni cells were grown to 2 × 10<sup>6</sup> to 2.5 × 10<sup>6</sup> cells/L, diluted in a 1:1 volume ratio with fresh media and infected with the recombinant baculovirus. Cells were harvested 72 h postinfection, resuspended in 25 mM Hepes, pH 7.4, and 1× protease inhibitor cocktail and snap-frozen in liquid N<sub>2</sub>.</p>
        <p>All protein purification steps were performed at 4 °C. Frozen cell pellets equivalent to 2 L of cell culture were thawed and resuspended at room temperature in 25 mM Hepes (pH 7.4), EDTA 1 mM, PMSF (0.5 mM), pepstatin (1 μg/mL) and leupeptin (1 μg/mL) or 1× protease inhibitor cocktail to give a final volume of 360 mL. The cells were centrifuged (120,000<bold><italic>g</italic></bold>, 2 h, 4 °C) to pellet the washed cells and membranes, the supernatant was carefully removed and the pellet was resupended in 240 mL of the same buffer. Cells were homogenised using a Polytron (12,000 rpm, 2 × 15 s on ice) and centrifuged to pellet the membranes (45,000<bold><italic>g</italic></bold>, 2 h, 4 °C). The pellet was resuspended in 25 mM Hepes (pH 7.4), PMSF (0.5 mM), pepstatin (1 μg/mL) and leupeptin (1 μg/mL) or 1× protease inhibitor cocktail, homogenised using a Polytron (12,000 rpm, 2 × 15 s on ice) and snap-frozen in liquid N<sub>2</sub>.</p>
        <p>Membranes were thawed at room temperature, diluted with 25 mM Hepes (pH 7.4), PMSF (0.5 mM), pepstatin (1 μg/mL) and leupeptin (1 μg/mL) or 1× protease inhibitor cocktail (100 mL). Membranes were pre-incubated with NECA at 100 μM for 45 min before solubilisation. Receptors were solubilised by adding DM and NaCl to give final concentrations of 1.5% and 0.3 M, respectively, followed by centrifugation (120,000<bold><italic>g</italic></bold>, 45 min, 4 °C). The solubilised receptor sample was then filtered through a 0.22-μm filter (Millipore) and applied at 0.3 mL/min to a 5-mL Ni-NTA superflow cartridge (Qiagen) pre-equilibrated with buffer [25 mM Hepes (pH 7.4), 0.1 M NaCl, 100 μM NECA, 0.15% DM and 2.5 mM imidazole]. The column was washed (1 mL/min) with the same buffer supplemented with 10, 40 or 80 mM imidazole for 5, 10 and 5 column volumes, respectively, and then eluted with 5 column volumes of elution buffer [25 mM Hepes (pH 7.4), 0.1 M NaCl, 100 μM NECA, 0.15% DM and 250 mM imidazole]. The eluted receptor was mixed with tobacco etch virus protease to cleave the tag for 4–6 h at 4 °C. After cleavage, 14–16 mL of the pooled fractions was concentrated to 2 mL using an Amicon-ultra spin concentrator (Ultracel-50K; Millipore) and loaded onto a PD-10 column (GE Healthcare) in order to remove the imidazole. A negative purification was used to remove the tobacco etch virus protease by loading the sample in batch onto 5 mL Ni-NTA (Qiagen) pre-equilibrated in 25 mM Hepes (pH 7.4), 0.1 M NaCl, 100 μM NECA, 0.15% DM and 40 mM imidazole and incubated for 30 min. The resin was spun down, and the supernatant containing the receptor was removed. For detergent exchange (into, e.g., 0.35% NG), the sample (5.5–6 mL) was concentrated down to 0.5 mL using an Amicon-ultra concentrator (Ultracel-50K; Millipore), diluted 10-fold in 25 mM Hepes (pH 7.4), 0.1 M NaCl, 100 μM NECA and 0.35% NG and concentrated down again to 0.3 to 0.5 mL. The protein sample was applied to a 10/30 S200 size-exclusion column pre-equilibrated in 25 mM Hepes (pH 7.4), 0.1 M NaCl, 100 μM NECA and 0.35% NG and run at 0.5 mL/min. Protein determination was performed using the amido black assay.<xref rid="bb0190" ref-type="bibr"><sup>38</sup></xref></p>
      </sec>
      <sec id="s0075">
        <title>Determination of receptor half-life (<italic>t</italic><sub>1/2</sub>) using the Arrhenius law</title>
        <p>For all the thermostabilisation studies carried out in our laboratory, the apparent <italic>T</italic><sub>m</sub> is the temperature for which 50% of the solubilised receptor remains folded after 30 min of incubation. The rate constant of the protein denaturation is a function of the temperature, and consequently, thermal denaturation of a protein can be compared to a chemical reaction for which the rate of the reaction is dependant on the temperature. Arrhenius established that any chemical reaction is temperature dependant. We used a simplified version of the Arrhenius law to estimate the <italic>t</italic><sub>1/2</sub> of A<sub>2A</sub>R: <italic>A</italic> = <italic>A</italic><sub>0</sub>exp(− 0.693 × <italic>t</italic>/<italic>t</italic><sub>1/2</sub>), in which <italic>A</italic> is the total sample activity, <italic>A</italic><sub>0</sub> is the activity for a defined temperature, <italic>t</italic> is the experimental time used for heating the sample and <italic>t</italic><sub>1/2</sub> is the half-life of A<sub>2A</sub>R bound to its agonist NECA. From the experimentally determined <italic>T</italic><sub>m</sub> curves, the values <italic>t</italic> and <italic>A</italic> were selected as being the slope of the curve, defining a window around the <italic>T</italic><sub>m</sub> value, which represents the linear part of the curve, from 26.5 °C to 32 °C for the WT, from 39 °C to 45 °C for GL0, from 44 °C to 50 °C for GL10 and from 47.5 °C to 53 °C for GL23. The reference measurement representing the total binding activity of the sample <italic>A</italic><sub>0</sub> was considered to be measured at 4 °C. From the graphical representation <italic>t</italic> = Log<sub>10</sub>(<italic>t</italic><sub>1/2</sub>) (<xref rid="f0010" ref-type="fig">Fig. 2</xref>c), we could extract a half-life for each construct at any temperature to define the improvement in stability of the various mutants compared to WT A<sub>2A</sub>R.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bb0005">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gloriam</surname>
              <given-names>D.E.</given-names>
            </name>
            <name>
              <surname>Fredriksson</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Schioth</surname>
              <given-names>H.B.</given-names>
            </name>
          </person-group>
          <article-title>The G protein-coupled receptor subset of the rat genome</article-title>
          <source>BMC Genomics</source>
          <volume>8</volume>
          <year>2007</year>
          <fpage>338</fpage>
          <pub-id pub-id-type="pmid">17892602</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0010">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kobilka</surname>
              <given-names>B.K.</given-names>
            </name>
            <name>
              <surname>Deupi</surname>
              <given-names>X.</given-names>
            </name>
          </person-group>
          <article-title>Conformational complexity of G-protein-coupled receptors</article-title>
          <source>Trends Pharmacol. Sci.</source>
          <volume>28</volume>
          <year>2007</year>
          <fpage>397</fpage>
          <lpage>406</lpage>
          <pub-id pub-id-type="pmid">17629961</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0015">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>DeWire</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Ahn</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Lefkowitz</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Shenoy</surname>
              <given-names>S.K.</given-names>
            </name>
          </person-group>
          <article-title>Beta-arrestins and cell signaling</article-title>
          <source>Annu. Rev. Physiol.</source>
          <volume>69</volume>
          <year>2007</year>
          <fpage>483</fpage>
          <lpage>510</lpage>
          <pub-id pub-id-type="pmid">17305471</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0020">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hopkins</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Groom</surname>
              <given-names>C.R.</given-names>
            </name>
          </person-group>
          <article-title>The druggable genome</article-title>
          <source>Nat. Rev., Drug Discov.</source>
          <volume>1</volume>
          <year>2002</year>
          <fpage>727</fpage>
          <lpage>730</lpage>
          <pub-id pub-id-type="pmid">12209152</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0025">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conn</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Christopoulos</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lindsley</surname>
              <given-names>C.W.</given-names>
            </name>
          </person-group>
          <article-title>Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders</article-title>
          <source>Nat. Rev., Drug Discov.</source>
          <volume>8</volume>
          <year>2009</year>
          <fpage>41</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="pmid">19116626</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0030">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cherezov</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Rosenbaum</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Hanson</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Rasmussen</surname>
              <given-names>S.G.</given-names>
            </name>
            <name>
              <surname>Thian</surname>
              <given-names>F.S.</given-names>
            </name>
            <name>
              <surname>Kobilka</surname>
              <given-names>T.S.</given-names>
            </name>
          </person-group>
          <article-title>High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor</article-title>
          <source>Science</source>
          <volume>318</volume>
          <year>2007</year>
          <fpage>1258</fpage>
          <lpage>1265</lpage>
          <pub-id pub-id-type="pmid">17962520</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0035">
        <label>7</label>
        <mixed-citation publication-type="other">Chien, E. Y., Liu, W., Zhao, Q., Katritch, V., Han, G. W., Hanson, M. A., et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330, 1091–1095.</mixed-citation>
      </ref>
      <ref id="bb0040">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jaakola</surname>
              <given-names>V.P.</given-names>
            </name>
            <name>
              <surname>Griffith</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Hanson</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Cherezov</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Chien</surname>
              <given-names>E.Y.</given-names>
            </name>
            <name>
              <surname>Lane</surname>
              <given-names>J.R.</given-names>
            </name>
          </person-group>
          <article-title>The 2.6 angstrom crystal structure of a human A<sub>2A</sub> adenosine receptor bound to an antagonist</article-title>
          <source>Science</source>
          <volume>322</volume>
          <year>2008</year>
          <fpage>1211</fpage>
          <lpage>1217</lpage>
          <pub-id pub-id-type="pmid">18832607</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0045">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warne</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Serrano-Vega</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>J.G.</given-names>
            </name>
            <name>
              <surname>Moukhametzianov</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>P.C.</given-names>
            </name>
            <name>
              <surname>Henderson</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Structure of a beta1-adrenergic G-protein-coupled receptor</article-title>
          <source>Nature</source>
          <volume>454</volume>
          <year>2008</year>
          <fpage>486</fpage>
          <lpage>491</lpage>
          <pub-id pub-id-type="pmid">18594507</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0050">
        <label>10</label>
        <mixed-citation publication-type="other">Wu, B., Chien, E. Y., Mol, C. D., Fenalti, G., Liu, W., Katritch, V., et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066–1071.</mixed-citation>
      </ref>
      <ref id="bb0055">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wacker</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Fenalti</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Katritch</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Abagyan</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Cherezov</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Stevens</surname>
              <given-names>R.C.</given-names>
            </name>
          </person-group>
          <article-title>Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography</article-title>
          <source>J. Am. Chem. Soc.</source>
          <volume>132</volume>
          <year>2010</year>
          <fpage>11443</fpage>
          <lpage>11445</lpage>
          <pub-id pub-id-type="pmid">20669948</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0060">
        <label>12</label>
        <mixed-citation publication-type="other">Rasmussen, S. G., Choi, H. J., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S., et al. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 469, 175–180.</mixed-citation>
      </ref>
      <ref id="bb0065">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosenbaum</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Lyons</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Holl</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Aragao</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Arlow</surname>
              <given-names>D.H.</given-names>
            </name>
          </person-group>
          <article-title>Structure and function of an irreversible agonist–beta(2) adrenoceptor complex</article-title>
          <source>Nature</source>
          <volume>469</volume>
          <year>2011</year>
          <fpage>236</fpage>
          <lpage>240</lpage>
          <pub-id pub-id-type="pmid">21228876</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0070">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warne</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Moukhametzianov</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>J.G.</given-names>
            </name>
            <name>
              <surname>Nehme</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>P.C.</given-names>
            </name>
            <name>
              <surname>Leslie</surname>
              <given-names>A.G.</given-names>
            </name>
          </person-group>
          <article-title>The structural basis for agonist and partial agonist action on a beta(1)-adrenergic receptor</article-title>
          <source>Nature</source>
          <volume>469</volume>
          <year>2011</year>
          <fpage>241</fpage>
          <lpage>244</lpage>
          <pub-id pub-id-type="pmid">21228877</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0075">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fredholm</surname>
              <given-names>B.B.</given-names>
            </name>
          </person-group>
          <article-title>Purinoceptors in the nervous system</article-title>
          <source>Pharmacol. Toxicol.</source>
          <volume>76</volume>
          <year>1995</year>
          <fpage>228</fpage>
          <lpage>239</lpage>
          <pub-id pub-id-type="pmid">7617551</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0080">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fredholm</surname>
              <given-names>B.B.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J.F.</given-names>
            </name>
            <name>
              <surname>Masino</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Vaugeois</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs</article-title>
          <source>Annu. Rev. Pharmacol. Toxicol.</source>
          <volume>45</volume>
          <year>2005</year>
          <fpage>385</fpage>
          <lpage>412</lpage>
          <pub-id pub-id-type="pmid">15822182</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0085">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hasko</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Linden</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Cronstein</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Pacher</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Adenosine receptors: therapeutic aspects for inflammatory and immune diseases</article-title>
          <source>Nat. Rev., Drug Discov.</source>
          <volume>7</volume>
          <year>2008</year>
          <fpage>759</fpage>
          <lpage>770</lpage>
          <pub-id pub-id-type="pmid">18758473</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0090">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jacobson</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>Z.G.</given-names>
            </name>
          </person-group>
          <article-title>Adenosine receptors as therapeutic targets</article-title>
          <source>Nat. Rev., Drug Discov.</source>
          <volume>5</volume>
          <year>2006</year>
          <fpage>247</fpage>
          <lpage>264</lpage>
          <pub-id pub-id-type="pmid">16518376</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0095">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hodgson</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Bertorelli</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Varty</surname>
              <given-names>G.B.</given-names>
            </name>
            <name>
              <surname>Lachowicz</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Forlani</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Fredduzzi</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Characterization of the potent and highly selective A<sub>2A</sub> receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7<italic>H</italic>-pyrazol o[4,3-<italic>e</italic>][1,2,4]triazolo[1,5-<italic>c</italic>]pyrimidin-5-amine] in rodent models of movement disorders and depression</article-title>
          <source>J. Pharmacol. Exp. Ther.</source>
          <volume>330</volume>
          <year>2009</year>
          <fpage>294</fpage>
          <lpage>303</lpage>
          <pub-id pub-id-type="pmid">19332567</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0100">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gether</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Ballesteros</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Seifert</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Sanders-Bush</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Weinstein</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kobilka</surname>
              <given-names>B.K.</given-names>
            </name>
          </person-group>
          <article-title>Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility</article-title>
          <source>J. Biol. Chem.</source>
          <volume>272</volume>
          <year>1997</year>
          <fpage>2587</fpage>
          <lpage>2590</lpage>
          <pub-id pub-id-type="pmid">9006889</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0105">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Serrano-Vega</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Magnani</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Shibata</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Tate</surname>
              <given-names>C.G.</given-names>
            </name>
          </person-group>
          <article-title>Conformational thermostabilization of the beta1-adrenergic receptor in a detergent-resistant form</article-title>
          <source>Proc. Natl Acad. Sci. USA</source>
          <volume>105</volume>
          <year>2008</year>
          <fpage>877</fpage>
          <lpage>882</lpage>
          <pub-id pub-id-type="pmid">18192400</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0110">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Serrano-Vega</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Tate</surname>
              <given-names>C.G.</given-names>
            </name>
          </person-group>
          <article-title>Transferability of thermostabilizing mutations between beta-adrenergic receptors</article-title>
          <source>Mol. Membr. Biol.</source>
          <volume>26</volume>
          <year>2009</year>
          <fpage>385</fpage>
          <lpage>396</lpage>
          <pub-id pub-id-type="pmid">19883298</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0115">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shibata</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>J.F.</given-names>
            </name>
            <name>
              <surname>Serrano-Vega</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Magnani</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Aloia</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Grisshammer</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Tate</surname>
              <given-names>C.G.</given-names>
            </name>
          </person-group>
          <article-title>Thermostabilization of the neurotensin receptor NTS1</article-title>
          <source>J. Mol. Biol.</source>
          <volume>390</volume>
          <year>2009</year>
          <fpage>262</fpage>
          <lpage>277</lpage>
          <pub-id pub-id-type="pmid">19422831</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0120">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Magnani</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Shibata</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Serrano-Vega</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Tate</surname>
              <given-names>C.G.</given-names>
            </name>
          </person-group>
          <article-title>Co-evolving stability and conformational homogeneity of the human adenosine A<sub>2A</sub> receptor</article-title>
          <source>Proc. Natl Acad. Sci. USA</source>
          <volume>105</volume>
          <year>2008</year>
          <fpage>10744</fpage>
          <lpage>10749</lpage>
          <pub-id pub-id-type="pmid">18664584</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0125">
        <label>25</label>
        <mixed-citation publication-type="other">Robertson, N., Jazayeri, A., Errey, J., Baig, A., Hurrell, E., Zhukov, A., et al. The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery. Neuropharmacology 60, 36–44.</mixed-citation>
      </ref>
      <ref id="bb0130">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warne</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Chirnside</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Schertler</surname>
              <given-names>G.F.</given-names>
            </name>
          </person-group>
          <article-title>Expression and purification of truncated, non-glycosylated turkey beta-adrenergic receptors for crystallization</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1610</volume>
          <year>2003</year>
          <fpage>133</fpage>
          <lpage>140</lpage>
          <pub-id pub-id-type="pmid">12586387</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0135">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tate</surname>
              <given-names>C.G.</given-names>
            </name>
            <name>
              <surname>Schertler</surname>
              <given-names>G.F.</given-names>
            </name>
          </person-group>
          <article-title>Engineering G protein-coupled receptors to facilitate their structure determination</article-title>
          <source>Curr. Opin. Struct. Biol.</source>
          <volume>19</volume>
          <year>2009</year>
          <fpage>386</fpage>
          <lpage>395</lpage>
          <pub-id pub-id-type="pmid">19682887</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0140">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rasmussen</surname>
              <given-names>S.G.</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Fung</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Pardon</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Casarosa</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Chae</surname>
              <given-names>P.S.</given-names>
            </name>
          </person-group>
          <article-title>Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor</article-title>
          <source>Nature</source>
          <volume>469</volume>
          <year>2011</year>
          <fpage>175</fpage>
          <lpage>180</lpage>
          <pub-id pub-id-type="pmid">21228869</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0145">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Standfuss</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>P.C.</given-names>
            </name>
            <name>
              <surname>Burghammer</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Oprian</surname>
              <given-names>D.D.</given-names>
            </name>
            <name>
              <surname>Schertler</surname>
              <given-names>G.F.</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of a thermally stable rhodopsin mutant</article-title>
          <source>J. Mol. Biol.</source>
          <volume>372</volume>
          <year>2007</year>
          <fpage>1179</fpage>
          <lpage>1188</lpage>
          <pub-id pub-id-type="pmid">17825322</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0150">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warne</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Serrano-Vega</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Tate</surname>
              <given-names>C.G.</given-names>
            </name>
            <name>
              <surname>Schertler</surname>
              <given-names>G.F.</given-names>
            </name>
          </person-group>
          <article-title>Development and crystallization of a minimal thermostabilized G protein-coupled receptor</article-title>
          <source>Protein Expression Purif.</source>
          <volume>65</volume>
          <year>2009</year>
          <fpage>204</fpage>
          <lpage>213</lpage>
        </element-citation>
      </ref>
      <ref id="bb0155">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luthin</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Olsson</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>R.D.</given-names>
            </name>
            <name>
              <surname>Sawmiller</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Linden</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Characterization of two affinity states of adenosine A<sub>2A</sub> receptors with a new radioligand, 2-[2-(4-amino-3-[125I]iodophenyl)ethylamino]adenosine</article-title>
          <source>Mol. Pharmacol.</source>
          <volume>47</volume>
          <year>1995</year>
          <fpage>307</fpage>
          <lpage>313</lpage>
          <pub-id pub-id-type="pmid">7870039</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0160">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murphree</surname>
              <given-names>L.J.</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Rieger</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>MacDonald</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Linden</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Human A(2A) adenosine receptors: high-affinity agonist binding to receptor-G protein complexes containing Gbeta(4)</article-title>
          <source>Mol. Pharmacol.</source>
          <volume>61</volume>
          <year>2002</year>
          <fpage>455</fpage>
          <lpage>462</lpage>
          <pub-id pub-id-type="pmid">11809871</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0165">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ballesteros</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Weinstein</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Integrated methods for the construction of three dimensional models and computational probing of structure function relations in G protein-coupled receptors</article-title>
          <source>Methods Neurosci.</source>
          <volume>25</volume>
          <year>1995</year>
          <fpage>366</fpage>
          <lpage>428</lpage>
        </element-citation>
      </ref>
      <ref id="bb0170">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Madabushi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Philippi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Meng</surname>
              <given-names>E.C.</given-names>
            </name>
            <name>
              <surname>Wensel</surname>
              <given-names>T.G.</given-names>
            </name>
            <name>
              <surname>Lichtarge</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <article-title>Evolutionary trace of G protein-coupled receptors reveals clusters of residues that determine global and class-specific functions</article-title>
          <source>J. Biol. Chem.</source>
          <volume>279</volume>
          <year>2004</year>
          <fpage>8126</fpage>
          <lpage>8132</lpage>
          <pub-id pub-id-type="pmid">14660595</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0175">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Urizar</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Claeysen</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Deupi</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Govaerts</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Costagliola</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Vassart</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Pardo</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>An activation switch in the rhodopsin family of G protein-coupled receptors: the thyrotropin receptor</article-title>
          <source>J. Biol. Chem.</source>
          <volume>280</volume>
          <year>2005</year>
          <fpage>17135</fpage>
          <lpage>17141</lpage>
          <pub-id pub-id-type="pmid">15722344</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0180">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jiang</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Van Rhee</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Yehle</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Wess</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Jacobson</surname>
              <given-names>K.A.</given-names>
            </name>
          </person-group>
          <article-title>Hydrophilic side chains in the third and seventh transmembrane helical domains of human A<sub>2A</sub> adenosine receptors are required for ligand recognition</article-title>
          <source>Mol. Pharmacol.</source>
          <volume>50</volume>
          <year>1996</year>
          <fpage>512</fpage>
          <lpage>521</lpage>
          <pub-id pub-id-type="pmid">8794889</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0185">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tate</surname>
              <given-names>C.G.</given-names>
            </name>
          </person-group>
          <article-title>Practical considerations of membrane protein instability during purification and crystallisation</article-title>
          <source>Methods Mol. Biol.</source>
          <volume>601</volume>
          <year>2010</year>
          <fpage>187</fpage>
          <lpage>203</lpage>
          <pub-id pub-id-type="pmid">20099147</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0190">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schaffner</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Weissmann</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>A rapid, sensitive, and specific method for the determination of protein in dilute solution</article-title>
          <source>Anal. Biochem.</source>
          <volume>56</volume>
          <year>1973</year>
          <fpage>502</fpage>
          <lpage>514</lpage>
          <pub-id pub-id-type="pmid">4128882</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <ack>
      <title>Acknowledgements</title>
      <p>This work was supported by core funding from the Medical Research Council and partly by a grant from Heptares Therapeutics Ltd. We would like to thank F. Magnani and T. Warne for helpful discussions on thermostabilisation, expression and purification and R. Henderson, A. Leslie and F. Marshall for comments on the manuscript.</p>
    </ack>
  </back>
  <floats-group>
    <fig id="f0005">
      <label>Fig. 1</label>
      <caption>
        <p>Positions of thermostabilising mutations in the primary sequence of human A<sub>2A</sub>R. The snake plot depicts the secondary structure elements found in the structure of A<sub>2A</sub>R, with the approximate position of the lipid bilayer shown in grey. (a) Thermostabilising mutations in the [<sup>3</sup>H]NECA-bound conformation are shown in orange. Mutations identified previously from [<sup>3</sup>H]NECA assays performed after heating the unliganded receptor are shown in red.<xref rid="bb0120" ref-type="bibr"><sup>24</sup></xref> Mutations that were selected by both assays are blue. (b) The 16 most thermostabilising mutations of the [<sup>3</sup>H]NECA-bound conformation of A<sub>2A</sub>R were re-assayed for thermostability in the antagonist-bound conformation using [<sup>3</sup>H]ZM241385 (<xref rid="t0005" ref-type="table">Table 1</xref>): magenta, mutants that did not bind antagonist in this assay; green, mutants that are less stable than WT A<sub>2A</sub>R in the antagonist-bound conformation; and brown, mutants that are more stable than WT in the antagonist-bound conformation.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="f0010">
      <label>Fig. 2</label>
      <caption>
        <p>Thermostability of agonist-bound, DDM-solubilised A<sub>2A</sub>R and thermostabilised mutants. (a) Additive effect of thermostabilising mutations used to generate A<sub>2A</sub>R-GL23. Predicted <italic>T</italic><sub>m</sub> values were calculated by adding the Δ<italic>T</italic><sub>m</sub> for each mutation (<xref rid="t0005" ref-type="table">Table 1</xref>) to the apparent <italic>T</italic><sub>m</sub> of WT A<sub>2A</sub>R. The broken line correlates with perfect additivity. WT A<sub>2A</sub>R is represented by a black diamond. The stabilities of the best thermostable mutants containing one, two or three point mutations are labelled, respectively, as follows: L48A (GL0), green diamond; L48A-Q89A (GL10), dark-blue diamond; and L48A-Q89A-T65A (GL23), red diamond. Other double mutants (light-blue diamonds) and triple mutants (light-red diamonds) that were less stable than the optimal combinations are also shown. (b) Thermostability assays were performed on receptors partially purified in 0.025% DDM and with [<sup>3</sup>H]NECA bound; A<sub>2A</sub>R (black circles), apparent <italic>T</italic><sub>m</sub> of 28.6 ± 0.2 °C, <italic>n</italic> = 8; GL0 (green squares), apparent <italic>T</italic><sub>m</sub> of 42.2 ± 1.0 °C, <italic>n</italic> = 5; GL10 (blue triangles), apparent <italic>T</italic><sub>m</sub> of 46.7 ± 0.4 °C, <italic>n</italic> = 3; and GL23 (red inverted triangles), apparent <italic>T</italic><sub>m</sub> of 49.9 ± 0.1 °C, <italic>n</italic> = 2. (c) Stability of mutants compared to WT A<sub>2A</sub>R based on <italic>t</italic><sub>1/2</sub> values calculated from (b) to allow the improvement in stability of the mutants compared to WT to be calculated: GL0, 49-fold; GL10, 136-fold; and GL23, 226-fold. The colour code is the same as in (b).</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
    <fig id="f0015">
      <label>Fig. 3</label>
      <caption>
        <p>Thermostability of the mutants GL23 and GL26. (a) Thermostability of GL26 (red squares; apparent <italic>T</italic><sub>m</sub> of 44.5 ± 0.8 °C, <italic>n</italic> = 3) and GL23 (blue circles; apparent <italic>T</italic><sub>m</sub> of 42.2 ± 0.3 °C, <italic>n</italic> = 2) after partial purification in DM (0.17%), both with [<sup>3</sup>H]NECA bound. (b) The thermostability of GL26 with [<sup>3</sup>H]NECA bound was determined by partially purifying the receptor in different detergents. GL26 was solubilised in DM and immobilised on Ni<sup>2+</sup>-NTA agarose, and then detergent exchange was performed. The results are from a single experiment performed in triplicate, with the final concentration of detergent indicated: 0.39% decanoyl-<italic>N</italic>-hydroxyethylglucamide (pink inverted triangles), apparent <italic>T</italic><sub>m</sub> of 42.3 °C; 0.17% decylmaltoside (red squares), apparent <italic>T</italic><sub>m</sub> of 42.0 °C; 0.3% NG (green inverted triangles), apparent <italic>T</italic><sub>m</sub> of 34.6 °C; 0.52% foscholine-10 (blue triangles), apparent <italic>T</italic><sub>m</sub> of 33.1 °C; 0.42% octylthioglucoside (orange circles), apparent <italic>T</italic><sub>m</sub> of 30.5 °C; 0.37% polyoxyethylene C8E4 (pale blue circles), apparent <italic>T</italic><sub>m</sub> of 26.4 °C.</p>
      </caption>
      <graphic xlink:href="gr3"/>
    </fig>
    <fig id="f0020">
      <label>Fig. 4</label>
      <caption>
        <p>Affinities of agonists and antagonists for A<sub>2A</sub>R and the thermostabilised mutants. (a and b) Competition binding experiments were performed by measuring the displacement of [<sup>3</sup>H]NECA bound to receptors in CHO cell membranes. Experiments were performed using three agonists (NECA, ATL146e and CGS21680) and two antagonists (CGS15943 and SCH58621) and the inverse agonist ZM241385 with example curves shown for ZM241385 (a) and NECA (b); WT A<sub>2A</sub>R, black circles; GL0, green squares; GL23, blue triangles; and GL26, red inverted triangles. Full data are shown in Table <xref rid="t0015" ref-type="table">3</xref>. (c) The differences in affinities (Δp<italic>K</italic><sub><italic>i</italic></sub>) between the WT A<sub>2A</sub>R and each of the mutants for the ligands tested were calculated from the p<italic>K</italic><sub><italic>i</italic></sub> values determined in <xref rid="t0015" ref-type="table">Table 3</xref>; GL0, green; GL23, blue; and GL26, red.</p>
      </caption>
      <graphic xlink:href="gr4"/>
    </fig>
    <fig id="f0025">
      <label>Fig. 5</label>
      <caption>
        <p>Purification of A<sub>2A</sub>R-GL31. The unglycosylated mutant of A<sub>2A</sub>R-GL26, A<sub>2A</sub>R-GL31, was expressed in insect cells using a recombinant baculovirus and purified on Ni<sup>2+</sup>-NTA. The receptor was further purified by size-exclusion chromatography (<italic>A</italic><sub>280</sub> trace is shown; void (<italic>V</italic><sub>0</sub>) and total (<italic>V</italic><sub>T</sub>) column volumes are indicated); this gave a symmetrical peak, which indicated that the preparation was monodisperse and homogenous. A Coomassie-blue-stained SDS-polyacrylamide gel (inset) showed that A<sub>2A</sub>R-GL31 represented a single band on the gel (left-hand lane) that was sufficiently pure for crystallisation (molecular weight markers are shown on the right).</p>
      </caption>
      <graphic xlink:href="gr5"/>
    </fig>
    <fig id="f0030">
      <label>Fig. 6</label>
      <caption>
        <p>Positions of the thermostabilising mutations in the antagonist-bound A<sub>2A</sub> structure. The structure of A<sub>2A</sub>R-StaR2 (Protein Data Bank code <ext-link ext-link-type="uri" xlink:href="pdb:3PWH">3PWH</ext-link>) thermostabilised in an antagonist-bound conformation is shown in rainbow colouration with the N-terminus and C-terminus labelled (N and C, respectively) and the bound antagonist ZM241385 depicted as a space-filling model (C, pink: N, blue; and O, red). The four amino acid residues mutated in A<sub>2A</sub>R to generate the thermostable mutant GL26 (L48A, Q89A, T65A and A54L) are depicted as space-filling models (dark grey). Note that the amino acid sequence shown is that of A<sub>2A</sub>R-StaR2, which also contains the A54L thermostabilising mutation,<xref rid="bb0125" ref-type="bibr"><sup>25</sup></xref> whereas Leu48, Gln89 and Thr65 are identical with WT A<sub>2A</sub>R.</p>
      </caption>
      <graphic xlink:href="gr6"/>
    </fig>
    <table-wrap id="t0005" position="float">
      <label>Table 1</label>
      <caption>
        <p>Thermostability of A<sub>2A</sub>R mutants with either agonist or antagonist bound</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="3" valign="bottom">A<sub>2A</sub>R mutation</th>
            <th align="center" rowspan="3" valign="bottom">Ballesteros–Weinstein</th>
            <th colspan="4" align="center" valign="top">Apparent <italic>T</italic><sub>m</sub> (°C)<hr/></th>
          </tr>
          <tr>
            <th colspan="2" align="center" valign="top">Agonist<hr/></th>
            <th colspan="2" align="center" valign="top">Antagonist<hr/></th>
          </tr>
          <tr>
            <th align="center" valign="top">[<sup>3</sup>H]NECA</th>
            <th align="center" valign="bottom">Δ<italic>T</italic><sub>m</sub></th>
            <th align="center" valign="top">[<sup>3</sup>H]ZM241385</th>
            <th align="center" valign="bottom">Δ<italic>T</italic><sub>m</sub></th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td valign="top">WT</td>
            <td align="center" valign="top">—</td>
            <td align="char" valign="top">28.5</td>
            <td align="center" valign="top">—</td>
            <td align="center" valign="top">32</td>
            <td align="center" valign="top">—</td>
          </tr>
          <tr>
            <td valign="top">V12A</td>
            <td align="center" valign="top">1.38</td>
            <td align="char" valign="top">30.5</td>
            <td align="center" valign="top">+ 2</td>
            <td align="center" valign="top">n.d.<xref rid="tf0005" ref-type="table-fn">a</xref></td>
            <td align="center" valign="top">n.d.</td>
          </tr>
          <tr>
            <td valign="top">S47A</td>
            <td align="center" valign="top">2.45</td>
            <td align="char" valign="top">31</td>
            <td align="center" valign="top">+ 2.5</td>
            <td align="center" valign="top">25.5</td>
            <td align="center" valign="top">− 6.5</td>
          </tr>
          <tr>
            <td valign="top">L48A</td>
            <td align="center" valign="top">2.46</td>
            <td align="char" valign="top">42.5</td>
            <td align="center" valign="top">+ 14</td>
            <td align="center" valign="top">0<xref rid="tf0010" ref-type="table-fn">b</xref></td>
            <td align="center" valign="top">n.d.</td>
          </tr>
          <tr>
            <td valign="top">A50L</td>
            <td align="center" valign="top">2.48</td>
            <td align="char" valign="top">31</td>
            <td align="center" valign="top">+ 2.5</td>
            <td align="center" valign="top">38.5</td>
            <td align="center" valign="top">+ 6.5</td>
          </tr>
          <tr>
            <td valign="top">A54L</td>
            <td align="center" valign="top">2.52</td>
            <td align="char" valign="top">33.5</td>
            <td align="center" valign="top">+ 5</td>
            <td align="center" valign="top">38</td>
            <td align="center" valign="top">+ 6</td>
          </tr>
          <tr>
            <td valign="top">V57A</td>
            <td align="center" valign="top">2.55</td>
            <td align="char" valign="top">34.5</td>
            <td align="center" valign="top">+ 6</td>
            <td align="center" valign="top">38</td>
            <td align="center" valign="top">+ 6</td>
          </tr>
          <tr>
            <td valign="top">F62A</td>
            <td align="center" valign="top">2.60</td>
            <td align="char" valign="top">31</td>
            <td align="center" valign="top">+ 2.5</td>
            <td align="center" valign="top">0</td>
            <td align="center" valign="top">n.d.</td>
          </tr>
          <tr>
            <td valign="top">T65A</td>
            <td align="center" valign="top">2.63</td>
            <td align="char" valign="top">33</td>
            <td align="center" valign="top">+ 4.5</td>
            <td align="center" valign="top">38</td>
            <td align="center" valign="top">+ 6</td>
          </tr>
          <tr>
            <td valign="top">F79A</td>
            <td align="center" valign="top">3.27</td>
            <td align="char" valign="top">31</td>
            <td align="center" valign="top">+ 2.5</td>
            <td align="center" valign="top">0</td>
            <td align="center" valign="top">n.d.</td>
          </tr>
          <tr>
            <td valign="top">F83A</td>
            <td align="center" valign="top">3.31</td>
            <td align="char" valign="top">30</td>
            <td align="center" valign="top">+ 1.5</td>
            <td align="center" valign="top">16.5</td>
            <td align="center" valign="top">− 15.5</td>
          </tr>
          <tr>
            <td valign="top">Q89A</td>
            <td align="center" valign="top">3.37</td>
            <td align="char" valign="top">34.5</td>
            <td align="center" valign="top">+ 6</td>
            <td align="center" valign="top">26</td>
            <td align="center" valign="top">− 8</td>
          </tr>
          <tr>
            <td valign="top">S90A</td>
            <td align="center" valign="top">3.38</td>
            <td align="char" valign="top">32</td>
            <td align="center" valign="top">+ 3.5</td>
            <td align="center" valign="top">32</td>
            <td align="center" valign="top">0</td>
          </tr>
          <tr>
            <td valign="top">A236L</td>
            <td align="center" valign="top">6.38</td>
            <td align="char" valign="top">31</td>
            <td align="center" valign="top">+ 2.5</td>
            <td align="center" valign="top">38</td>
            <td align="center" valign="top">+ 6</td>
          </tr>
          <tr>
            <td valign="top">I238A</td>
            <td align="center" valign="top">6.40</td>
            <td align="char" valign="top">31</td>
            <td align="center" valign="top">+ 2.5</td>
            <td align="center" valign="top">36</td>
            <td align="center" valign="top">+ 4</td>
          </tr>
          <tr>
            <td valign="top">F242A</td>
            <td align="center" valign="top">6.44</td>
            <td align="char" valign="top">31</td>
            <td align="center" valign="top">+ 2.5</td>
            <td align="center" valign="top">0</td>
            <td align="center" valign="top">n.d.</td>
          </tr>
          <tr>
            <td valign="top">V282A</td>
            <td align="center" valign="top">7.47</td>
            <td align="char" valign="top">30.5</td>
            <td align="center" valign="top">+ 2</td>
            <td align="center" valign="top">33</td>
            <td align="center" valign="top">+ 1</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>Values were determined from a single thermostability curve with values determined in triplicate with an estimated error of ± 0.5 °C. These values were used to give a rank order of thermostabilisation for the different mutants. For final values for WT A<sub>2A</sub>R and L48A (GL0), please refer to <xref rid="t0010" ref-type="table">Table 2</xref>.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tf0005">
          <label>a</label>
          <p>Not determined.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tf0010">
          <label>b</label>
          <p>No binding detected at antagonist concentration used.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="t0010" position="float">
      <label>Table 2</label>
      <caption>
        <p>Combinations of mutants tested for thermostabilising the NECA-bound conformation of A<sub>2A</sub>R</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="2" valign="top"/>
            <th align="center" rowspan="2" valign="bottom">Mutant name</th>
            <th align="center" rowspan="2" valign="bottom">A<sub>2A</sub>R mutations</th>
            <th colspan="3" align="center" valign="top">Apparent <italic>T</italic><sub>m</sub> in DDM (°C)<hr/></th>
          </tr>
          <tr>
            <th align="center" valign="top">Predicted</th>
            <th align="center" valign="top">Single measurement<xref rid="tf0015" ref-type="table-fn">a</xref></th>
            <th align="center" valign="top">Final values<xref rid="tf0015" ref-type="table-fn">a</xref></th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td valign="top">WT A<sub>2A</sub>R</td>
            <td align="center" valign="top">—</td>
            <td align="center" valign="top">—</td>
            <td align="center" valign="top">—</td>
            <td align="center" valign="top">—</td>
            <td align="center" valign="top">28.6 ± 0.2 (<italic>n</italic> = 8)</td>
          </tr>
          <tr>
            <td valign="top">Single mutant</td>
            <td align="center" valign="top">GL0</td>
            <td align="center" valign="top">L48A</td>
            <td align="char" valign="top">42.5</td>
            <td align="char" valign="top">42.5</td>
            <td align="center" valign="top">42.2 ± 1.0 (<italic>n</italic> = 5)</td>
          </tr>
          <tr>
            <td rowspan="13" valign="top">Double mutant</td>
            <td align="center" valign="top">GL1</td>
            <td align="center" valign="top">L48A-V12A</td>
            <td align="char" valign="top">45</td>
            <td align="char" valign="top">45.5</td>
            <td align="center" valign="top"/>
          </tr>
          <tr>
            <td align="center" valign="top">GL4</td>
            <td align="center" valign="top">L48A-A54L</td>
            <td align="char" valign="top">47.5</td>
            <td align="char" valign="top">46</td>
            <td align="center" valign="top"/>
          </tr>
          <tr>
            <td align="center" valign="top">GL5</td>
            <td align="center" valign="top">L48A-V57A</td>
            <td align="char" valign="top">48.5</td>
            <td align="char" valign="top">41.5</td>
            <td align="center" valign="top"/>
          </tr>
          <tr>
            <td align="center" valign="top">GL6</td>
            <td align="center" valign="top">L48A-F62A</td>
            <td align="char" valign="top">45</td>
            <td align="char" valign="top">45</td>
            <td align="center" valign="top"/>
          </tr>
          <tr>
            <td align="center" valign="top">GL7</td>
            <td align="center" valign="top">L48A-T65A</td>
            <td align="char" valign="top">47</td>
            <td align="char" valign="top">45</td>
            <td align="center" valign="top"/>
          </tr>
          <tr>
            <td align="center" valign="top">GL8</td>
            <td align="center" valign="top">L48A-F79A</td>
            <td align="char" valign="top">45</td>
            <td align="char" valign="top">45.5</td>
            <td align="center" valign="top"/>
          </tr>
          <tr>
            <td align="center" valign="top">GL9</td>
            <td align="center" valign="top">L48A-F83A</td>
            <td align="char" valign="top">44</td>
            <td align="char" valign="top">43.5</td>
            <td align="center" valign="top"/>
          </tr>
          <tr>
            <td align="center" valign="top">GL10</td>
            <td align="center" valign="top">L48A-Q89A</td>
            <td align="char" valign="top">48.5</td>
            <td align="char" valign="top">47.5</td>
            <td align="center" valign="top">46.7 ± 0.4 (<italic>n</italic> = 3)</td>
          </tr>
          <tr>
            <td align="center" valign="top">GL11</td>
            <td align="center" valign="top">L48A-S90A</td>
            <td align="char" valign="top">46</td>
            <td align="char" valign="top">46</td>
            <td align="center" valign="top"/>
          </tr>
          <tr>
            <td align="center" valign="top">GL14</td>
            <td align="center" valign="top">L48A-A236L</td>
            <td align="char" valign="top">45</td>
            <td align="char" valign="top">40.5</td>
            <td align="center" valign="top"/>
          </tr>
          <tr>
            <td align="center" valign="top">GL15</td>
            <td align="center" valign="top">L48A-I238A</td>
            <td align="char" valign="top">45</td>
            <td align="char" valign="top">42.5</td>
            <td align="center" valign="top"/>
          </tr>
          <tr>
            <td align="center" valign="top">GL17</td>
            <td align="center" valign="top">L48A-F242A</td>
            <td align="char" valign="top">45</td>
            <td align="char" valign="top">39.5</td>
            <td align="center" valign="top"/>
          </tr>
          <tr>
            <td align="center" valign="top">GL19</td>
            <td align="center" valign="top">L48A-V282A</td>
            <td align="char" valign="top">44.5</td>
            <td align="char" valign="top">40</td>
            <td align="center" valign="top"/>
          </tr>
          <tr>
            <td rowspan="5" valign="top">Triple mutant</td>
            <td align="center" valign="top">GL20</td>
            <td align="center" valign="top">L48A-Q89A-V12A</td>
            <td align="char" valign="top">49.5</td>
            <td align="char" valign="top">46</td>
            <td align="center" valign="top"/>
          </tr>
          <tr>
            <td align="center" valign="top">GL21</td>
            <td align="center" valign="top">L48A-Q89A-A54L</td>
            <td align="char" valign="top">52</td>
            <td align="char" valign="top">46</td>
            <td align="center" valign="top"/>
          </tr>
          <tr>
            <td align="center" valign="top">GL22</td>
            <td align="center" valign="top">L48A-Q89A-F62A</td>
            <td align="char" valign="top">49.5</td>
            <td align="char" valign="top">45.5</td>
            <td align="center" valign="top"/>
          </tr>
          <tr>
            <td align="center" valign="top">GL24</td>
            <td align="center" valign="top">L48A-Q89A-F79A</td>
            <td align="char" valign="top">49.5</td>
            <td align="char" valign="top">46</td>
            <td align="center" valign="top"/>
          </tr>
          <tr>
            <td align="center" valign="top">GL23</td>
            <td align="center" valign="top">L48A-Q89A-T65A</td>
            <td align="char" valign="top">51.5</td>
            <td align="char" valign="top">50</td>
            <td align="center" valign="top">49.9 ± 0.1 (<italic>n</italic> = 2)</td>
          </tr>
          <tr>
            <td colspan="6" valign="top">  </td>
          </tr>
          <tr>
            <td rowspan="2" valign="top"/>
            <td align="center" rowspan="2" valign="top"/>
            <td align="center" rowspan="2" valign="top"/>
            <td colspan="3" align="center" valign="top">Apparent <italic>T</italic><sub>m</sub> in DM (°C)</td>
          </tr>
          <tr>
            <td colspan="6">
              <hr/>
            </td>
          </tr>
          <tr>
            <td align="center" valign="top">Predicted</td>
            <td align="center" valign="top">Single measurement<xref rid="tf0015" ref-type="table-fn">a</xref></td>
            <td align="center" valign="top">Final values<xref rid="tf0015" ref-type="table-fn">a</xref></td>
          </tr>
          <tr>
            <td colspan="6">
              <hr/>
            </td>
          </tr>
          <tr>
            <td valign="top">Triple mutant</td>
            <td align="center" valign="top">GL23</td>
            <td align="center" valign="top">L48A-Q89A-T65A</td>
            <td align="char" valign="top"/>
            <td align="char" valign="top"/>
            <td align="center" valign="top">42.2 ± 0.3 (<italic>n</italic> = 2)</td>
          </tr>
          <tr>
            <td rowspan="4" valign="top">Quadruple mutant</td>
            <td align="center" valign="top">GL25</td>
            <td align="center" valign="top">L48A-Q89A-T65A-A50L</td>
            <td align="char" valign="top">46</td>
            <td align="char" valign="top">44.5</td>
            <td align="center" valign="top"/>
          </tr>
          <tr>
            <td align="center" valign="top">GL26</td>
            <td align="center" valign="top">L48A-Q89A-T65A-A54L</td>
            <td align="char" valign="top">49</td>
            <td align="char" valign="top">46</td>
            <td align="center" valign="top">44.5 ± 0.8 (<italic>n</italic> = 3)</td>
          </tr>
          <tr>
            <td align="center" valign="top">GL27</td>
            <td align="center" valign="top">L48A-Q89A-T65A-F83A</td>
            <td align="char" valign="top">44.5</td>
            <td align="char" valign="top">44</td>
            <td align="center" valign="top"/>
          </tr>
          <tr>
            <td align="center" valign="top">GL29</td>
            <td align="center" valign="top">L48A-Q89A-T65A- S263A</td>
            <td align="char" valign="top">44.5</td>
            <td align="char" valign="top">44.5</td>
            <td align="center" valign="top"/>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tf0015">
          <label>a</label>
          <p>Values were determined initially from a single thermostability curve, with measurements performed in triplicate, to find the most thermostable mutants; replicate experiments were performed only for key mutants. Predicted <italic>T</italic><sub>m</sub> was calculated from the parental experimental <italic>T</italic><sub>m</sub> value (single or double mutants) and the value of the Δ<italic>T</italic><sub>m</sub> for the single mutant tested. Experimental measurements were then compared with the predicted <italic>T</italic><sub>m</sub> and classified as (i) an additive effect when the experimental value is equal or similar to the predicted <italic>T</italic><sub>m</sub> (± 1.5 °C) and (ii) nonadditive when the experimental value is different from the predicted <italic>T</italic><sub>m</sub>. Quadruple mutants were tested in DM.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="t0015" position="float">
      <label>Table 3</label>
      <caption>
        <p>Comparison of affinities of agonist and antagonist binding to A<sub>2A</sub>R and thermostable mutants</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="2" valign="top"/>
            <th rowspan="2" valign="top"/>
            <th colspan="4" align="center" valign="top">p<italic>K</italic><sub><italic>i</italic></sub> (− Log M)<hr/></th>
          </tr>
          <tr>
            <th align="center" valign="top">WT</th>
            <th align="center" valign="top">GL0</th>
            <th align="center" valign="top">GL23</th>
            <th align="center" valign="top">GL26</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="3" valign="top">Agonist</td>
            <td align="center" valign="top">NECA</td>
            <td align="char" valign="top">7.82 ± 0.20</td>
            <td align="char" valign="top">7.94 ± 0.06</td>
            <td align="char" valign="top">8.43 ± 0.07⁎</td>
            <td align="char" valign="top">8.13 ± 0.11</td>
          </tr>
          <tr>
            <td align="center" valign="top">ATL146e</td>
            <td align="char" valign="top">7.95 ± 0.17</td>
            <td align="char" valign="top">7.96 ± 0.01</td>
            <td align="char" valign="top">8.25 ± 0.01</td>
            <td align="char" valign="top">7.85 ± 0.08</td>
          </tr>
          <tr>
            <td align="center" valign="top">CGS21680</td>
            <td align="char" valign="top">6.94 ± 0.11</td>
            <td align="char" valign="top">6.89 ± 0.05</td>
            <td align="char" valign="top">7.24 ± 0.19</td>
            <td align="char" valign="top">6.77 ± 0.06</td>
          </tr>
          <tr>
            <td rowspan="3" valign="top">Antagonist</td>
            <td align="center" valign="top">ZM241385</td>
            <td align="char" valign="top">9.22 ± 0.04</td>
            <td align="char" valign="top">7.65 ± 0.17⁎⁎⁎</td>
            <td align="char" valign="top">6.89 ± 0.06⁎⁎⁎</td>
            <td align="char" valign="top">6.67 ± 0.08⁎⁎⁎</td>
          </tr>
          <tr>
            <td align="center" valign="top">CGS15943</td>
            <td align="char" valign="top">9.68 ± 0.11</td>
            <td align="char" valign="top">7.91 ± 0.06⁎⁎⁎</td>
            <td align="char" valign="top">7.49 ± 0.10⁎⁎⁎</td>
            <td align="char" valign="top">7.17 ± 0.08⁎⁎⁎</td>
          </tr>
          <tr>
            <td align="center" valign="top">SCH58621</td>
            <td align="char" valign="top">8.92 ± 0.17</td>
            <td align="char" valign="top">6.97 ± 0.06⁎⁎⁎</td>
            <td align="char" valign="top">7.10 ± 0.12⁎⁎⁎</td>
            <td align="char" valign="top">4.61 ± 0.20⁎⁎⁎</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>Competition experiments were performed by displacement of [<sup>3</sup>H]NECA from receptors transiently expressed in CHO cells. The p<italic>K</italic><sub><italic>i</italic></sub> values are the mean of three independent experiments performed in triplicate ± standard error of the mean. p<italic>K</italic><sub><italic>i</italic></sub> values were calculated from the IC<sub>50</sub> using the Cheng–Prusoff equation and the following values for <italic>K</italic><sub>d</sub> (nM) for [<sup>3</sup>H]NECA: WT, 13.45 ± 0.44; GL0, 6.39 ± 0.59⁎⁎⁎; GL23, 4.65 ± 0.67⁎⁎⁎; and GL26, 6.33 ± 0.66⁎⁎⁎. <italic>P</italic> values were determined using a one-way ANOVA with Dunnett's post-hoc test: ⁎, <italic>P</italic> &lt; 0.05; ⁎⁎⁎, <italic>P</italic> &lt; 0.001 with respect to the WT A<sub>2A</sub>R.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>